Observation on the effect of intravenous levocarnitine combined with cyclic adenosine monophosphate in the treatment of viral myocarditis
Objective:To explore the specific efficacy of intravenous infusion of levocarnitine combined with cyclic adenosine monophosphate(cAMP)for the treatment of viral myocarditis(VMC).Methods:64 VMC patients admitted to our hospital from January 2020 to December 2022 were selected and randomly divided into two groups according to the random numbertablemethod,with32patientsineachgroup.ThecontrolgroupwasgivenacAMPinjection(40mgdissolvedin 250 ml of 5%glucose injection)once a day.The observation group was administered L-carnitine injection 10～20 mg/kg dissolved in 250 ml of 5%glucose intravenously,once a day.Both groups were treated for 14 days.Clinical efficacy,serum inflammatory factors,myocardial injury markers,and adverse reactions were compared between the two groups.Results:The total effective rate of the observation group was 96.88%(31/32),significantly higher than that of the control group 71.88%(23/32),and the difference was statistically significant(P＜0.05).Before treatment,there were no significant differences in interleukin-4(IL-4),interleukin-6(IL-6),tumor necrosis factor-α(TNF-α),and interferon-γ(IFN-γ)between the two groups(P＞0.05).After treatment,the levels of IL-4 in the observation group were higher than those in the control group,while the levels of IL-6,TNF-α,and IFN-γ were significantly lower in the observation group than in the control group(P＜0.05).Before treatment,there was no significant difference in cardiac troponin T(cTnT),creatine kinase isoenzyme(CK-MB),and plasma N-terminal brain natriuretic peptide precursor(NT-proBNP)levels between the two groups(P＞0.05).After treatment,cTnT,CK-MB,and NT-proBNP levels were significantly lower in the observation group than in the control group(P＜0.05).The incidence of adverse reactions in the observation group was 15.63%(5/32)compared with 9.38%(3/32)in the control group,and the difference was not statistically significant(P＞0.05).Conclusion:The combination of levocarnitine and cAMP treatment can enhance the clinical efficacy of VMC patients to a certain extent,further alleviate inflammatory reactions,reduce myocardial injury,and have high drug safety.
NETL
NSTL
万方数据
